Following this treatment, the patient’s symptoms and laboratory parameters stabilized ... This search was performed using the PubMed database with keywords such as “ANCA-associated vasculitis,” ...

Well, we are very excited that we have multiple development in the study of treatment of vasculitis, and this is all because ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...

Sinusitis can cause facial pressure, sinus headache, and other symptoms. Treatment may depend on the cause. A sinus infection, also known as sinusitis or rhinosinusitis, occurs when your nasal ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome. The drug remains one of GSK's top products, with sales of £856 million ($1.1 billion) in the first half of this year ...

Vasculitis in pregnancy is probably underdiagnosed and under-reported; cases of vasculitis are rare and so disease flares may not always be recognized by a general clinician. Preconceptual ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...

including chronic rhinosinusitis with nasal polyps and eosinophilic granulomatosis with polyangiitis. It has previously modelled peak sales for the new drug of around £3 billion a year.